Monica Stonehill

Healio spoke with Marlyn Mayo, MD, about increased research focused on symptoms of primary sclerosing cholangitis presented at The Liver Meeting, as well as treatments being investigated.“Traditionally, we haven’t paid a lot of attention to symptoms in PSC, except when patients have acute cholangitis,” Mayo, professor of internal medicine at UT Southwestern Medical Center, said.

In this video, Marlyn Mayo, MD, discusses data from a real-world case series investigating the efficacy and safety of maralixibat in eight patients with primary sclerosing cholangitis.“What they found was impressive — almost complete resolution of pruritus in the patients,” Mayo, professor of internal medicine at UT Southwestern Medical Center, told Healio.

Linerixibat decreased serum interleukin-31 levels in patients with primary biliary in cholangitis after 24 weeks, which may be linked to an improvement in pruritus and response to treatment, according to data presented at The Liver Meeting.“Interleukin-31 (IL-31) has been identified as a potential pruritogen in cholestatic pruritus,” Christopher Bowlus, MD, chief of gastroenterology

PHOENIX — In this video, Paul Kwo, MD, discusses preliminary results from the phase 3 MAESTRO-NAFLD-1 trial assessing resmetirom in patients with compensated metabolic dysfunction-associated steatohepatitis cirrhosis.“There’s a larger effort ongoing, but this initial glimpse suggests that there may be benefit to resmetirom in patients with cirrhosis, in addition to its known

PHOENIX — Use of rifaximin soluble solid dispersion tablets for up to 24 weeks did not increase infection-related adverse events among patients with cirrhosis, according to data presented at ACG Annual Scientific Meeting.Findings also showed no antibiotic-resistant infections associated with its use.

PHOENIX — In this video, Mazen Noureddin, MD, MHSc, professor of medicine at Houston Methodist, highlights current treatments and others in the pipeline for metabolic dysfunction-associated steatohepatitis.Two medications are currently approved for MASH with fibrosis: Rezdiffra (resmetirom, Madrigal Pharmaceuticals), an oral thyroid hormone receptor-beta selective agonist, and Wegovy

PHOENIX — In this video, Medora D. Rodrigues, MD, MPH, discusses results of retrospective cohort study that showed tirzepatide was linked to a lower risk for biliary disease compared with semaglutide.“For patients who have been treated with semaglutide and tirzepatide for diabetes and weight loss management, clinicians can make a better decision between these two medications,

Currently, more than 300 million people are diagnosed with hepatitis around the world, according to the World Hepatitis Alliance. Cases continue to rise, with more than 2 million new cases each year. Among the five hepatitis viruses, HBV, HCV and HDV usually cause chronic disease, liver cancer and cirrhosis, whereas HAV and HEV cause acute disease but may lead to more serious complications in

Physiological metrics captured via wearable devices may help identify and predict flares in inflammatory bowel disease, Robert P. Hirten, MD, told Healio, and could potentially play a role in remote monitoring of disease activity. “As gastroenterologists, one of the things that we find is that between office visits, there sometimes can be relatively little contact or interaction between

Approximately 14% of the U.S. population lives in rural areas, where access to health care may be limited by insurance coverage, geography and infrastructure, and provider shortages, according to HHS. Known as “medical deserts,” these areas can lead to higher morbidity and mortality as well as adverse effects on health services.